About Karolinska Development
Karolinska Development is a publicly listed company based in Solna (Sweden) founded in 2003. Early-stage life science investments in Sweden are targeted. Its chief executive, as recorded, is Johan Dighed. Karolinska Development offers products and services including Life Science Investments and Portfolio Management. Its focus areas include Investment Industry, Venture Capital Funds, Independent Funds and Conventional VCs. Its legal entity is Karolinska Development AB.
Company details
Founded in 2003 and based in Solna, Sweden, investments are directed toward early-stage startups in the life sciences sector, including bio pharma, diagnostics, and biotech. Operations center on venture capital funding for innovative companies within these areas. Notable portfolio entries include Aprea, BioArctic Neuroscience, Dilafor, and Forendo Pharma Oy, with leadership provided by figures such as CEO Conny Bogentoft and Deputy CEO Johan Dighed.
- Headquarters Solna, Sweden
- Stage Public
- SectorsFinancial Services
- Email••••••••
- Phone•••• ••••
- Website karolinskadevelopment.com
- Social LinkedIn X
- Legal Name Karolinska Development Ab Class B
- Annual Revenue$1.17 M (USD)86.38as on Dec 31, 2025
- Net Profit-$21.05 M (USD)-2292.98as on Dec 31, 2025
- EBITDA-$20.97 M (USD)-2266.46as on Dec 31, 2025
Products & Services of Karolinska Development
Karolinska Development offers a comprehensive portfolio of products and services, including Life Science Investments and Portfolio Management.
Investments are made in pharmaceutical and medtech companies to support innovation
Portfolios of current and former companies are managed and monitored for performance
People of Karolinska Development
18 people are tracked at Karolinska Development (10 in leadership, 5 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Johan Dighed | Deputy CEO | Leadership |
Conny Bogentoft | CEO | Leadership |
Yan Cheng | President | Leadership |
Viktor Drvota | CEO | Leadership |
Fredrik Järrsten | Chief Financial Officer | Leadership |
Eva Montgomerie | Head of Accounting | Leadership |
John Öhd | Chief Scientific Officer | Leadership |
Eva Skarin Montgomerie | Head Of Accounting | Leadership |
Hans Christopher Toll | Chief Financial Officer | Leadership |
Per Aniansson | Investment Director | Leadership |
Björn Cochlovius | Board member | Board & advisors |
Hans Wigzell | Chairman | Board & advisors |
Tse Ping | Vice Chairman | Board & advisors |
Magnus Persson | Board member | Board & advisors |
Theresa Tse | Board member | Board & advisors |
Mikaela Sörman | Analyst | Team |
Linda Spahiu | Investment Manager | Team |
Elisabet Gimbringer | Financial Manager | Team |
Complete people profiles for Karolinska Development
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Karolinska Development
Karolinska Development is a publicly listed company on the OMXSTO with ticker symbol KDEV in Sweden, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Apr 2011
- Listed onNASDAQ OMX: KDEV
- Listed entityKarolinska Development AB Class B
- Exchange sectorFinance
- ISINSE0002190926
- Share price0.27 SEK (+4.45% on the day) · 2026-02-09
- Market capitalisation244,131,705.00 SEK
- EPS (diluted, trailing year)-0.41 SEK
- Volume (last session)529,407
- Analyst consensusNo rating
Financials of Karolinska Development
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 10.8M SEK | -193.8M SEK | -193.1M SEK |
| 2024 | 5.8M SEK | -8.1M SEK | -8.2M SEK |
| 2023 | 2.8M SEK | 5.4M SEK | -1.1M SEK |
| 2022 | 3.0M SEK | -88.1M SEK | -88.0M SEK |
| 2021 | -25.8M SEK | 170.8M SEK | 161.4M SEK |
Detailed financial statements for Karolinska Development
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Karolinska Development
The website of Karolinska Development (karolinskadevelopment.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▲ 110.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Karolinska Development
Complete news archive for Karolinska Development
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Karolinska Development
Karolinska Development was founded in 2003.
Karolinska Development is headquartered in Solna, Sweden.
Johan Dighed is the CEO of Karolinska Development, as recorded in our data.
Annual revenue of Karolinska Development is $1.17M as on Dec 31, 2025.
Founded in 2003 and based in Solna, Sweden, investments are directed toward early-stage startups in the life sciences sector, including bio pharma, diagnostics, and biotech. Operations center on venture capital funding for innovative companies within these areas. Notable portfolio entries include Aprea, BioArctic Neuroscience, Dilafor, and Forendo Pharma Oy, with leadership provided by figures such as CEO Conny Bogentoft and Deputy CEO Johan Dighed.
Karolinska Development offers Life Science Investments and Portfolio Management.
Yes, Karolinska Development is publicly traded on OMXSTO under the ticker symbol KDEV.
Karolinska Development operates through Karolinska Development Ab.